From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...

As Vertex Therapeutics nears completion of a historic FDA submission, the rare disease specialist has depicted a rosy launch picture for what could become the first CRISPR-based gene editing therapy.

VRTX operates within healthcare sector of S&P 500, as CASGEVY expansion highlights evolving genetic medicine and rare disease ...

Eric N. Olson, PhD, of the the University of Texas Southwestern Medical Center, co-founder and chief science advisor of Exonics Therapeutics. The company is being acquired by Vertex Pharmaceuticals ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Vertex Pharmaceuticals has pulled out of a planned four-year collaboration with Verve Therapeutics, returning all rights to a preclinical gene editing program for liver disease. Verve announced the ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Vertex Pharmaceuticals has two clinical-stage programs for type 1 diabetes, each employing different methods for preventing the immune system from rejecting the cell therapies. For a third program in ...

Gene editing is an emerging field, and Vertex Pharmaceuticals Incorporated VRTX is plunging headlong into it with two deals announced Thursday after the market close. Vertex also entered into an ...